Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › primary sclerosing cholangitis

Primary sclerosing cholangitis

Part of Bile Duct Diseases

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for primary sclerosing cholangitis

10 trials tracked for primary sclerosing cholangitis: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 117 citations.

10Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 6 Phase 1 3
  1. Phase 3 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed · 117 cited
  2. Phase 2 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC) Completed
  3. Phase 2 Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) Completed
  4. Phase 2 A Study of NGM282 in Patients With Primary Sclerosing Cholangitis Completed
  5. Phase 2 Vidofludimus Calcium for Primary Sclerosing Cholangitis Completed
  6. Phase 2 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Completed
Show 4 more trials
  1. Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Completed
  2. Phase 1 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT Completed
  3. Phase 1 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed
  4. Phase 1 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Primary sclerosing cholangitis: what the trials found

Clinical evidence for the management of primary sclerosing cholangitis includes studies evaluating Vancomycin in Phase 1 and Phase 3 trials [2, 8, 10].

In a Phase 1 trial involving Vancomycin (N=35), treatment over 12 weeks resulted in significant reductions in Alkaline Phosphatase levels from baseline 10.

Recent results — preliminary, needs further review

  • PLN-74809 was evaluated in a Phase 2 study (N=121) 1.

For the clinician treating this condition

  • Vancomycin has been investigated across multiple phases, with evidence showing significant reductions in Alkaline Phosphatase levels over 12 weeks of treatment 10.
  • Newer agents such as PLN-74809 are currently undergoing Phase 2 investigation 1.

AI synthesis of 2 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Oncology Meta-analysis
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Apr 28, 2026